Form 4: AVITA Medical Director Equity Compensation Disclosure

Director Woody Joseph Fralin reports the acquisition of restricted stock units and stock options following shareholder approval.

Summary

• Director Woody Joseph Fralin acquired 40,547 restricted stock units (RSUs) on January 5, 2026.
• Director Fralin acquired 22,214 RSUs on January 20, 2026.
• The director was granted 29,446 stock options at an exercise price of $3.47 on January 5, 2026.
• The director was granted 16,133 stock options at an exercise price of $3.77 on January 20, 2026.
• All equity grants were subject to shareholder approval, which was formally obtained on June 3, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Formal shareholder approval obtained for all director equity grants.

Negatives

• Dilutive impact of new equity grants on existing shareholders.

Risks

• Potential for future share price volatility affecting the value of granted options.
• Dependence on continued company performance to meet vesting criteria.

Future Outlook

The equity grants are subject to time-based vesting schedules, with RSUs vesting annually and options vesting over three years, incentivizing long-term director retention.

Management Comments

• The grants were subject to the approval of the Company's stockholders, which was obtained on June 3, 2026.

Industry Context

StockSavvy.ai notes that standardizing director compensation through equity grants is a common practice in the medical device sector to ensure board alignment with long-term shareholder value creation.

Comparison to Industry Standards

• Equity-based compensation for non-executive directors is consistent with peer medical technology companies.
• Vesting schedules align with standard corporate governance practices for board members.

Corporate Governance

Stakeholder Impact

• Shareholders: Minor dilution from new equity issuance.
• Director: Increased alignment with company performance.

Next Steps

• Vesting of RSUs in annual installments starting 12 months from grant dates.
• Vesting of stock options in three equal annual installments.

Key Dates

Keywords

AVITA Medical, RCEL, Form 4, Director Compensation, Equity Grants, Insider Ownership